Hyung Joon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyung Joon Kim has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Young Tae Kim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
4 shared publications - Hyun Woong Lee
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea
3 shared publications - Eileen Laurel Yoon
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
2 shared publications - Eunju Kim
Department of Gastroenterology, Chung-Ang University College of Medicine, Seoul, Korea
2 shared publications - Hyun Phil Shin
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea
2 shared publications - Hyun Yang
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Early Antiviral Therapy and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: A Prospective Phase II Study
Dong Hyun Sinn, Ji Hoon Kim, Hyung Joon Kim, June Sung Lee, Jae Young Jang, Kyunga Kim, Joonghyun Ahn, Yoon Jun Kim, Joon Hyeok Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260219
- 7 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessEarly Antiviral Therapy and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: A Prospective Phase II Study
Dong Hyun Sinn, Ji Hoon Kim, Hyung Joon Kim, June Sung Lee, Jae Young Jang, Kyunga Kim, Joonghyun Ahn, Yoon Jun Kim, Joon Hyeok Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260219
- Open Access
- 30 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 665-680
Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes. This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs. Eighty-eight studies were included, comprising 8,839 patients with HCC who were treated with DAAs. The pooled SVR rate in patients with HCC was 89% (95% confidence interval [CI], 87% to 91%). However, the SVR varied significantly depending on tumor viability; patients with non-viable HCC had the highest SVR (91%), followed by those with mixed (88%) and viable HCC (84%). The SVR was significantly lower in the HCC group than in the non-HCC group (risk ratio [RR], 0.95; 95% CI, 0.92 to 0.98). In 28 studies reporting on recurrence outcomes, patients with HCC who were treated with DAAs had a 40% lower recurrence risk than non-DAA-treated patients (RR, 0.60; 95% CI, 0.49 to 0.75). Pooled analyses of adjusted estimates showed that DAA treatment was independently associated with reduced recurrence (hazard ratio [HR], 0.47; 95% CI, 0.32 to 0.70) and all-cause mortality (HR, 0.40; 95% CI, 0.31 to 0.51). An SVR was linked to an improved prognosis, with lower recurrence (HR, 0.43; 95% CI, 0.31 to 0.61) and mortality (HR, 0.41; 95% CI, 0.14 to 1.24) risks. DAAs are effective in patients with HCC. Despite slightly lower SVR rates than in patients without HCC, the overall benefits support the use of antiviral therapy in patients with HCC.
- 30 June 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (4) , 665-680
Open AccessEfficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes. This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs. Eighty-eight studies were included, comprising 8,839 patients with HCC who were treated with DAAs. The pooled SVR rate in patients with HCC was 89% (95% confidence interval [CI], 87% to 91%). However, the SVR varied significantly depending on tumor viability; patients with non-viable HCC had the highest SVR (91%), followed by those with mixed (88%) and viable HCC (84%). The SVR was significantly lower in the HCC group than in the non-HCC group (risk ratio [RR], 0.95; 95% CI, 0.92 to 0.98). In 28 studies reporting on recurrence outcomes, patients with HCC who were treated with DAAs had a 40% lower recurrence risk than non-DAA-treated patients (RR, 0.60; 95% CI, 0.49 to 0.75). Pooled analyses of adjusted estimates showed that DAA treatment was independently associated with reduced recurrence (hazard ratio [HR], 0.47; 95% CI, 0.32 to 0.70) and all-cause mortality (HR, 0.40; 95% CI, 0.31 to 0.51). An SVR was linked to an improved prognosis, with lower recurrence (HR, 0.43; 95% CI, 0.31 to 0.61) and mortality (HR, 0.41; 95% CI, 0.14 to 1.24) risks. DAAs are effective in patients with HCC. Despite slightly lower SVR rates than in patients without HCC, the overall benefits support the use of antiviral therapy in patients with HCC.
- Open Access
- 1 April 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 32 (2) , 921-923
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
- 1 April 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 32 (2) , 921-923
Open AccessRethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
- Open Access
- 30 September 2025
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 25 (2) , 160-168
Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria
This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications. In response to discrepancies between national reimbursement policies and clinical decision-making, members of the Korean Liver Cancer Association and Korean Association for the Study of the Liver participated in a web-based survey from February 4 to 14, 2025. A total of 89 respondents, primarily experienced clinicians, provided their views on major clinical scenarios including infiltrative HCC, bilobar multifocal disease, huge tumors, vascular invasion, extrahepatic metastasis, and transarterial chemoembolization (TACE) refractoriness. There was high agreement for including infiltrative HCC (69.7%), suspected portal vein invasion (70.8%), and TACE refractoriness (82.0%) as systemic therapy indications. TACE refractoriness, in particular, aligns with current guideline definitions. Additionally, over half of respondents (51.7%) supported extrahepatic metastasis under similar conditions. Notably, multidisciplinary discussion was emphasized across scenarios, but many respondents also favored allowing primary physician discretion in select cases. This report provides consolidated expert input to inform future updates to reimbursement policies and promote alignment with real-world clinical practice. These findings may help bridge the gap between national coverage criteria and clinical decision in systemic therapy for HCC.
- 30 September 2025
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 25 (2) , 160-168
Open AccessExpert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria
This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications. In response to discrepancies between national reimbursement policies and clinical decision-making, members of the Korean Liver Cancer Association and Korean Association for the Study of the Liver participated in a web-based survey from February 4 to 14, 2025. A total of 89 respondents, primarily experienced clinicians, provided their views on major clinical scenarios including infiltrative HCC, bilobar multifocal disease, huge tumors, vascular invasion, extrahepatic metastasis, and transarterial chemoembolization (TACE) refractoriness. There was high agreement for including infiltrative HCC (69.7%), suspected portal vein invasion (70.8%), and TACE refractoriness (82.0%) as systemic therapy indications. TACE refractoriness, in particular, aligns with current guideline definitions. Additionally, over half of respondents (51.7%) supported extrahepatic metastasis under similar conditions. Notably, multidisciplinary discussion was emphasized across scenarios, but many respondents also favored allowing primary physician discretion in select cases. This report provides consolidated expert input to inform future updates to reimbursement policies and promote alignment with real-world clinical practice. These findings may help bridge the gap between national coverage criteria and clinical decision in systemic therapy for HCC.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (11) , e92
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
Kim HJ, et al. J Korean Med Sci. 2022 Mar;37(11):e92. https://doi.org/10.3346/jkms.2022.37.e92
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (11) , e92
Open AccessA Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
Kim HJ, et al. J Korean Med Sci. 2022 Mar;37(11):e92. https://doi.org/10.3346/jkms.2022.37.e92
- Open Access
- 1 January 2020
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 32 (1) , 69-73
Diffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report
Systemic sclerosis (SSc) is a chronic systemic disease of unknown etiology characterized by vasculopathy, excessive accumulation of extracellular matrix, and fibrosis of the skin and other internal organs. Although its etiology remains elusive, approximately one third of SSc patients presents with additional autoimmune disease, which suggests that an autoimmune mechanism is a major component of the underlying pathophysiology. On the other hand, primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) are two main autoimmune liver diseases. A 41-year-old female previously diagnosed with PBC/AIH overlap syndrome presented with multiple, painful brownish to erythematous firm patches on the hands, arms, axillae, neck, abdomen, and thighs. Laboratory work-up yielded positive results for anti-nuclear antibody, anti-Ro/Sjogren's-syndrome-related antigen A autoantibodies, and perinuclear anti-neutrophil cytoplasmic antibodies while punch biopsy of her left hand showed characteristics that are consistent with scleroderma. Herein, we report the first case of a patient with diffuse cutaneous SSc and concurrent PBC/AIH overlap syndrome and suggest that this coexistence of multiple autoimmune diseases is not a coincidence but rather that a common autoimmune pathogenesis may exist.
- 1 January 2020
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 32 (1) , 69-73
Open AccessDiffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report
Systemic sclerosis (SSc) is a chronic systemic disease of unknown etiology characterized by vasculopathy, excessive accumulation of extracellular matrix, and fibrosis of the skin and other internal organs. Although its etiology remains elusive, approximately one third of SSc patients presents with additional autoimmune disease, which suggests that an autoimmune mechanism is a major component of the underlying pathophysiology. On the other hand, primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) are two main autoimmune liver diseases. A 41-year-old female previously diagnosed with PBC/AIH overlap syndrome presented with multiple, painful brownish to erythematous firm patches on the hands, arms, axillae, neck, abdomen, and thighs. Laboratory work-up yielded positive results for anti-nuclear antibody, anti-Ro/Sjogren's-syndrome-related antigen A autoantibodies, and perinuclear anti-neutrophil cytoplasmic antibodies while punch biopsy of her left hand showed characteristics that are consistent with scleroderma. Herein, we report the first case of a patient with diffuse cutaneous SSc and concurrent PBC/AIH overlap syndrome and suggest that this coexistence of multiple autoimmune diseases is not a coincidence but rather that a common autoimmune pathogenesis may exist.
- Open Access
- 1 July 2008
- Published by SAGE Publications in Antiviral Therapy
- Vol. 14 (5) , 705-712
Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir
Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)- positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg serocon-version, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351), HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%), IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.
- 1 July 2008
- Published by SAGE Publications in Antiviral Therapy
- Vol. 14 (5) , 705-712
Open AccessRescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir
Background: The efficacy of adefovir dipivoxil (ADV) or entecavir (ETV) rescue monotherapy has not been directly compared in hepatitis B e antigen (HBeAg)- positive patients with lamivudine (3TC)-resistant chronic hepatitis B (CHB). We compared the efficacy of ADV and ETV rescue monotherapy in HBeAg-positive patients with confirmed genotypic 3TC resistance. Methods: A total of 160 HBeAg-positive patients with confirmed 3TC resistance underwent switch therapy (91 ADV and 59 ETV). Parameters assessed included alanine aminotransferase (ALT) normalization, HBeAg serocon-version, undetectable serum hepatitis B virus (HBV) DNA by PCR (lower detection limit <300 copies/ml), virological breakthrough and initial virological response (IVR) at 3 (IVR-3) and 6 (IVR-6) months. Results: Following 52 weeks of treatment in the ADV and ETV groups, serum HBV DNA became undetectable in 25 (27.5%) and 21 (35.6%; P=0.292) patients, ALT normalization occurred in 67/78 (85.9%) and 43/47 (91.5%; P=0.351), HBeAg seroconversion in 4 (4.4%) and 1 (1.7%; P=1.000), IVR-3 in 19 (20.9%) and 18 (30.5%), IVR-6 in 40 (44.0%) and 25 (42.4%) and virological breakthrough in 2 (2.2%) and 1 (1.7%; P=1.000) patients, respectively. Conclusions: ADV and ETV revealed comparable efficacy after 52 weeks of treatment in HBeAg-positive patients with 3TC resistance. Undetectable HBV DNA in serum following 52 weeks of treatment was predictable with IVR-3 and IVR-6 in both groups.